GlassScriptPhysician profile
Gregory H Carlsen
NPI 1306831516
$3,909.79
in general payments reported to CMS, 2019-2025
45 companies · $662 in 2025
The $662 reported for 2025 was more than what 79% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $647 · 2020: $273 · 2021: $404 · 2022: $602 · 2023: $791 · 2024: $531 · 2025: $662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,984.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,984.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $514.92 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Merck Sharp & Dohme LLC | $395.27 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Amgen INC. | $346.71 | 2019-2023 | Lumakras, Kyprolis, Blincyto |
| Astrazeneca Pharmaceuticals LP | $219.98 | 2019-2025 | Tagrisso, Enhertu |
| Genzyme Corporation | $162.24 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $161.49 | 2020-2025 | |
| Astellas Pharma US INC | $160.51 | 2020-2024 | Padcev |
| Boston Scientific Corporation | $152.75 | 2019-2025 | Spaceoar Vue System - 10ml |
| Takeda Pharmaceuticals U.S.A., INC. | $145.05 | 2019-2025 | Ninlaro, Fruzaqla |
| Abbvie INC. | $118.74 | 2023-2025 | Venclexta |
| Incyte Corporation | $114.66 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Genmab U.S., INC. | $89.26 | 2023-2025 | Tivdak, Epkinly |
| Bayer Healthcare Pharmaceuticals INC. | $89.18 | 2019-2025 | |
| Coherus Oncology, INC. | $86.80 | 2021-2023 | |
| Emd Serono, INC. | $86.20 | 2022-2024 | Bavencio |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Carlsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.